CNAT Conatus Pharmaceuticals Inc.

0.83
+0.12  (+17%)
Previous Close 0.71
Open 0.72
Price To Book 1
Market Cap 27563533
Shares 33,165,122
Volume 2,622,833
Short Ratio
Av. Daily Volume 1,228,417

NewsSee all news

  1. Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
  2. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  3. Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?
  4. Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
  5. Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data due mid-2019.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b data released December 5, 2018 did not meet primary endpoint. 48-week liver function data due mid-2019.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2b data released April 4, 2018. Primary endpoint not met.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b trial did not meet primary endpoint - March 21, 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis
Phase 2 data released September 2015.
Emricasan
Portal Hypertension

Latest News

  1. Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
  2. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  3. Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?
  4. Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
  5. Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
  6. Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
  7. Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
  8. Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
  9. Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
  10. Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT
  11. Implied Volatility Surging for Conatus (CNAT) Stock Options
  12. Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
  13. Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
  14. Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates
  15. Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
  16. Is Conatus Pharmaceuticals Inc.’s (NASDAQ:CNAT) CEO Pay Justified?
  17. Conatus (CNAT) Completes Enrollment in Phase II NASH Study
  18. Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
  19. Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
  20. Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?